Sanofi (SNY)
(Delayed Data from NSDQ)
$53.10 USD
+1.90 (3.71%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $53.09 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$53.10 USD
+1.90 (3.71%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $53.09 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth C Momentum C VGM
Zacks News
AstraZeneca's Forxiga Gets EC Approval for Type-I Diabetes
by Zacks Equity Research
AstraZeneca's (AZN) diabetes drug gets approval in Europe for type-1 diabetes as an adjunct to insulin in patients with a BMI greater or equal to 27 kg/m2.
Biogen Stock Crashes on Termination of Alzheimer's Studies
by Zacks Equity Research
Biogen (BIIB) and its Japanese partner, Eisai discontinue two late-stage studies evaluating aducanumab, in patients with Alzheimer's disease.
Emergent Begins Phase III Study on Anthrax Vaccine AV7909
by Zacks Equity Research
Emergent (EBS) kicks off a late-stage study on its investigational anthrax vaccine AV7909.
Regeneron, Sanofi Get EC Nod for Label Expansion of Praluent
by Zacks Equity Research
Regeneron (REGN) and partner Sanofi receives approval in Europe for the label expansion of Praluent to reduce cardiovascular (CV) risk in adults with established atherosclerotic CV disease.
Lexicon Pharma Initiates Dosing in Biliary Tract Cancer Study
by Zacks Equity Research
Lexicon Pharma (LXRX) commences dosing of first patient in phase IIa study evaluating its marketed drug, Xermelo, in biliary tract cancer.
Biotech Stock Roundup: REGN Gets FDA Nod for Dupixent & Other Pipeline News
by Zacks Equity Research
Key highlights of the past week are regulatory and pipeline developments.
Should Value Investors Consider Sanofi (SNY) Stock Now?
by Zacks Equity Research
Let's see if Sanofi (SNY) stock is a good choice for value-oriented investors right now from multiple angles.
Regeneron/Sanofi's Dupixent Gets FDA Nod for Label Expansion
by Zacks Equity Research
The FDA approves a label expansion of Regeneron's (REGN) asthma drug, Dupixent for moderate-to-severe atopic dermatitis in adolescents.
Sanofi's Dupixent Gets FDA Priority Status for Nasal Polyps
by Zacks Equity Research
Sanofi (SNY) and partner Regeneron's (REGN) Dupixent gets FDA's priority review status for inadequately controlled severe chronic rhinosinusitis with nasal polyps.
Roche's (RHHBY) sNDA for Flu Candidate Accepted by the FDA
by Zacks Equity Research
The FDA accepts Roche's (RHHBY) sNDA for Xofluza to treat influenza in people at high risk of complications.
Top Stock Reports for Salesforce, Booking Holdings & VMware
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including salesforce (CRM), Booking Holdings (BKNG) and VMware (VMW).
Lilly to Bring Half-Priced Version of Popular Humalog Insulin
by Zacks Equity Research
Eli Lilly (LLY) plans to launch a cheaper version of its popular insulin, Humalog amid increasing pressure to lower drug costs.
What's in the Cards for Novavax (NVAX) This Earnings Season?
by Zacks Equity Research
Novavax (NVAX) is expected to provide updates on its lead vaccine candidate, Resvax when it reports fourth-quarter 2018 results.
Regeneron-Sanofi Get CHMP Nod for Dupixent Label Expansion
by Zacks Equity Research
The CHMP gives a positive opinion for the label expansion of Regeneron (REGN) and Sanofi's Dupixent for the treatment of asthma in Europe.
Pharma Stock Roundup: Roche to Buy ONCE, Lawmakers Grill CEOs Over High Drug Prices
by Zacks Equity Research
Roche (RHHBY) to buy Spark Therapeutics for $4.8 billion. Executives of big pharma companies face senators' questions over high drug prices.
Sanofi/Regeneron Disagree With Jury Verdict in Amgen's Favor
by Zacks Equity Research
Sanofi (SNY) and partner Regeneron (REGN) disagree with a jury verdict in favor of Amgen upholding the validity of two patents related to Repatha.
Emergent (EBS) Q4 Earnings, Revenues Surpass Estimates
by Zacks Equity Research
Emergent (EBS) rides high on both earnings and a revenue beat in Q4.
BioMarin (BMRN) Q4 Earnings & Sales Miss, Shares Decline
by Zacks Equity Research
BioMarin (BMRN) misses estimates for earnings and revenues in the fourth quarter. Shares decline in after-hours trading.
Ascendis Pharma Files IND for Hypoparathyroidism Candidate
by Zacks Equity Research
Ascendis Pharma (ASND) submits regulatory application to initiate a phase II study in the United States on its hypoparathyroidism therapy candidate, TransCon PTH.
Sanofi/Regeneron Cut Price of PCSK9 Inhibitor Praluent by 60%
by Zacks Equity Research
Sanofi (SNY) and Regeneron (REGN) announce a 60% cut in the U.S. list price of their cholesterol lowering drug, Praluent to improve access and affordability of the product.
ImmunoGen (IMGN) Beats on Earnings & Sales in Q4, Shares Up
by Zacks Equity Research
ImmunoGen (IMGN) reports narrower-than-expected loss in Q4 and beats revenue estimates.
Pharma Stock Roundup: Q4 Earnings at MRK, LLY, CHMP Nod for Several Drugs
by Zacks Equity Research
Merck (MRK) and Lilly (LLY) report Q4 results. CHMP gives nod to several drugs.
Alnylam's (ALNY) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Alnylam (ALNY) incurs wider year-over-year loss in the fourth quarter of 2018.
Sanofi (SNY) Q4 Earnings Top, Genzyme Unit Drives Sales Growth
by Zacks Equity Research
Sanofi (SNY) beat estimates for earnings and missed the same for sales in the fourth quarter. The Specialty Care unit drove top-line growth.
Regeneron Q4 Earnings & Sales Beat on Strong Dupixent, Eylea
by Zacks Equity Research
Regeneron's (REGN) earnings and sales surpass expectations in Q4 on solid Dupixent and Eylea sales.